Novo Nordisk A/S Financial Statements FY2022-FY2026Q3

Novo Nordisk A/S (NVO) Financial Statements in Beancount — Open Ledger

Novo Nordisk's income statement and balance sheet, FY2022 through FY2026Q3, as a public, auditable plain-text Beancount ledger — reconstructed line by line from the company's own Form 20-F and 6-K filings and version-controlled in git. Part of the Open Ledger project on beancount.io.

Browse it live: beancount.io/ledger/open_ledger/novo-nordisk

Latest analysis: Novo Nordisk Q3 2026 Earnings: Sales Up 4%, Reported Profit Down 16% on DKK 8.7B of Write-Downs

Key Figures

Amounts in MDKK (millions of Danish kroner), exactly as the ledger records them.

What's Inside

Fiscal years end December 31 (SEC CIK 0000353278); amounts are in millions of Danish kroner as reported. FY2022 comes from the Annual Report 2022, FY2023–FY2025 from the full-year financial reports (company announcements) on SEC EDGAR, and FY2026H1 is the six months ended June 30, 2026 from the half-year financial report furnished on Form 6-K.

Quick Start

uvx --from beancount bean-check main.bean
uvx --from beanquery bean-query main.bean \
  "SELECT year, sum(position) WHERE account ~ '^Income:Revenue' GROUP BY year ORDER BY year"

Zero output from bean-check means the ledger is internally consistent: every
income statement sums to zero and every balance-sheet snapshot reconciles to
the filed totals. The query prints revenue by calendar year; income is a
credit, so it shows as a negative number. Open main.bean in Fava
or import it into beancount.io to explore it visually.

Methodology

• Balance sheet — pad / balance directives assert each period-end
  figure against the filing named in that period file's source banner.
• Income statement — one zero-sum transaction per period: Income
  negative (credit), Expenses positive (debit), with the arithmetic check in
  a comment directly above it.
• Unit — MDKK; 175,311 MDKK means 175,311 million Danish kroner.

Analysis

• Novo Nordisk Q3 2026 Earnings: Sales Up 4%, Reported Profit Down 16% on DKK 8.7B of Write-Downs — FY2026Q3
• Novo Nordisk H1 2026 Earnings: DKK 175.3B Sales, DKK 69.5B Net Profit, Outlook 'Raised' to 0% to −6% — FY2026H1

Corrections

Found a figure that does not match the filing? Email
[email protected] with the period, the account
and the filing page. Corrections are committed with the source cited.

About Open Ledger

Open Ledger is a growing library of public-company financial statements
published as plain-text accounting at
beancount.io/ledger — git-versioned, diffable
across companies, and auditable against primary filings. Read the analysis
behind the numbers on the beancount.io blog.

Disclaimer

This ledger is an independent reconstruction of Novo Nordisk A/S's publicly filed
financial statements, provided for educational and informational purposes
only. It is not investment, financial, legal, tax, or accounting advice, and
is not an offer or recommendation to buy or sell any security. Beancount.io is
not affiliated with, endorsed by, or sponsored by Novo Nordisk A/S; all trademarks
belong to their respective owners. Figures may contain errors, omissions, or
simplifications and may lag the latest filings — the company's own regulatory
filings are the authoritative source. Provided "as is" without warranty of any
kind; use at your own risk.